The SEPT9 and SDC2 methylation levels were higher in 94.7% (18/19) and 100.0% (19/19) of cancer tissues than in their paired adjacent paracancer tissues (p < 0.001, Figure 1), thus making the ColoDefense assay a candidate method for CRC screening. The gene discussed is SEPTIN9; the disease is cancer.